Phototherapy for Psoriasis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight

Phototherapy for Psoriasis Treatment Market

(Albnay, USA) DelveInsight’s Phototherapy for Psoriasis Market Insights report proffers a detailed comprehension of the Phototherapy for Psoriasis market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Phototherapy for Psoriasis market size from 2019 to 2032 segmented into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan).

The Phototherapy for Psoriasis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Phototherapy for Psoriasis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Phototherapy for Psoriasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Phototherapy for Psoriasis market.

Request for sample report @ Phototherapy for Psoriasis Market Outlook

Some of the salient features from the Phototherapy for Psoriasis Market Report:

• Phototherapy for Psoriasis market is expected to grow at a decent CAGR by 2032.
• DelveInsight analysts suggested that the Phototherapy for Psoriasis market size is expected to increase drastically owing to the launches of several potential emerging therapies during the study period.
• Key pharmaceutical Phototherapy for Psoriasis companies such as Phothera, Bristol Myers Squibb, Zerigo Health, Solarc Systems Inc, Dermalux and others are reported to bring a significant shift in the Phototherapy for Psoriasis.
• In 2022, the total diagnosed prevalent cases of psoriasis in the US were ~8 million, projected to increase during the forecast period (2023–2032).
• In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.
• In September 2022, Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1,2Sotyktu is not recommended for use in combination with other potent immunosuppressants.

For further information on the market impact by therapies, download the Phototherapy for Psoriasis sample @ Phototherapy for Psoriasis Therapeutic Scenario

Phototherapy for Psoriasis Overview

Phototherapy is a widely used treatment for psoriasis, leveraging controlled exposure to ultraviolet (UV) light to reduce inflammation and slow the excessive growth of skin cells. The primary types of phototherapy include narrowband UVB (NB-UVB), broadband UVB, psoralen plus UVA (PUVA), and targeted laser treatments such as the excimer laser. These therapies are particularly beneficial for moderate to severe psoriasis cases that do not respond well to topical treatments.

The demand for phototherapies is driven by their cost-effectiveness, non-invasive nature, and efficacy in managing psoriasis symptoms. Advancements in technology have led to the development of home-based phototherapy devices, improving accessibility for patients. Additionally, increased awareness and favorable reimbursement policies in some regions have further boosted market adoption.

However, market growth is hindered by safety concerns associated with long-term UV exposure, which increases the risk of skin cancer. The availability of biologic and systemic treatments, which offer targeted mechanisms with fewer side effects, also poses competition. Furthermore, high equipment costs and limited access to treatment centers, especially in developing regions, remain significant challenges.

Despite these barriers, the phototherapy market is expected to grow due to ongoing research and technological advancements, ensuring safer and more efficient treatment options for psoriasis patients.

Phototherapy for Psoriasis Epidemiology Segmentation

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Psoriasis Epidemiology Segmentation:

The Psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Diagnosed Prevalence of Psoriasis in Adults
• Diagnosed Prevalence of Psoriasis in Paediatrics
• Diagnosed Prevalence of Psoriasis by Types
• Diagnosed Prevalence of Psoriasis by Location
• Diagnosed Prevalence of Psoriasis by Severity

Keen to learn how Phototherapy for Psoriasis Epidemiological Trends are going to appear in 2032 for the 7MM, Download @ Phototherapy for Psoriasis Prevalence

Phototherapy for Psoriasis Market Outlook

The Phototherapies for Psoriasis Market is driven by several key factors, primarily the increasing global prevalence of psoriasis, which is fueling demand for effective treatment options like phototherapy. Technological advancements, including excimer laser therapy and targeted UVB treatments, have enhanced efficacy and patient convenience, further promoting market expansion. Additionally, rising awareness and improved diagnostic rates have led to higher patient adoption of phototherapy. Favorable reimbursement policies in some regions are improving accessibility, while the cost-effectiveness and minimally invasive nature of phototherapy make it an attractive alternative to biologics and systemic treatments. Moreover, the rising demand for home-based phototherapy devices is expanding market penetration, particularly in areas with limited healthcare access. However, several barriers hinder market growth, including safety concerns related to long-term UV exposure, which increases the risk of skin cancer. The availability of alternative treatments, such as biologics and systemic therapies with higher efficacy, poses significant competition. Furthermore, the high initial cost of phototherapy equipment, restricted access to specialized treatment centers in rural areas, and stringent regulatory requirements for device approval limit widespread adoption. Despite these challenges, continuous research and development efforts are expected to drive innovation and improve the safety and effectiveness of phototherapy solutions for psoriasis management.

Discover more about therapy set to grab substantial Phototherapy for Psoriasis market share @ Phototherapy for Psoriasis Treatment Market

Scope of the Phototherapy for Psoriasis Market Report

• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Phototherapy for Psoriasis Companies: Phothera, Bristol Myers Squibb, Zerigo Health, Solarc Systems Inc, Dermalux and others
• Phototherapy for Psoriasis Therapeutic Assessment: Phototherapy for Psoriasis current marketed and emerging therapies
• Phototherapy for Psoriasis Dynamics: Phototherapy for Psoriasis drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Phototherapy for Psoriasis Access and Reimbursement

Request for sample report @ https://www.delveinsight.com/sample-request/phototherapies-for-psoriasis-market

Table of Contents

1. Key Insights

2. Report Introduction

3. Phototherapy for Psoriasis Market Overview at a Glance

4. Executive Summary of Phototherapy for Psoriasis

5. Phototherapy for Psoriasis Epidemiology and Market Methodology

6. Phototherapy for Psoriasis: Disease Background and Overview

7. Diagnosis of Phototherapy for Psoriasis

8. Phototherapy for Psoriasis Treatment

9. Conclusion for Phototherapy for Psoriasis

10. Phototherapy for Psoriasis Epidemiology and Patient Population

11. Phototherapy for Psoriasis Patient Journey

12. Key Endpoints in Phototherapy for Psoriasis Clinical Trials

13. Phototherapy for Psoriasis Marketed Therapies

14. Phototherapy for Psoriasis Emerging Therapies

15. Phototherapy for Psoriasis: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Phototherapy for Psoriasis Market Drivers

19. Phototherapy for Psoriasis Market Barriers

20. Phototherapy for Psoriasis SWOT Analysis

21. Phototherapy for Psoriasis Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting